Inovio Pharmaceuticals Inc (INO)
4.06
+0.09
(+2.27%)
USD |
NASDAQ |
Nov 21, 16:00
4.065
0.00 (0.00%)
After-Hours: 20:00
Inovio Pharmaceuticals Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.1008M |
| March 31, 2024 | |
| December 31, 2023 | 0.1027M |
| September 30, 2023 | 0.3884M |
| June 30, 2023 | 0.226M |
| March 31, 2023 | 0.1149M |
| December 31, 2022 | 0.1247M |
| September 30, 2022 | 9.154M |
| June 30, 2022 | 0.7844M |
| March 31, 2022 | 0.1991M |
| December 31, 2021 | 0.8391M |
| September 30, 2021 | 0.2917M |
| June 30, 2021 | 0.2728M |
| March 31, 2021 | 0.3711M |
| December 31, 2020 | 5.581M |
| September 30, 2020 | 0.2362M |
| June 30, 2020 | 0.2672M |
| March 31, 2020 | 1.327M |
| December 31, 2019 | 0.2795M |
| September 30, 2019 | 0.8669M |
| June 30, 2019 | 0.1357M |
| March 31, 2019 | 2.830M |
| December 31, 2018 | 2.503M |
| September 30, 2018 | 2.001M |
| June 30, 2018 | 24.45M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.530M |
| December 31, 2017 | 8.787M |
| September 30, 2017 | 2.644M |
| June 30, 2017 | 20.41M |
| March 31, 2017 | 10.38M |
| December 31, 2016 | 8.514M |
| September 30, 2016 | 12.54M |
| June 30, 2016 | 6.204M |
| March 31, 2016 | 8.110M |
| December 31, 2015 | 5.936M |
| September 30, 2015 | 24.18M |
| June 30, 2015 | 5.287M |
| March 31, 2015 | 5.167M |
| December 31, 2014 | 2.457M |
| September 30, 2014 | 1.840M |
| June 30, 2014 | 3.802M |
| March 31, 2014 | 2.358M |
| December 31, 2013 | 1.740M |
| September 30, 2013 | 9.487M |
| June 30, 2013 | 0.7856M |
| March 31, 2013 | 1.455M |
| December 31, 2012 | 1.135M |
| September 30, 2012 | 0.8547M |
| June 30, 2012 | 0.4361M |
| March 31, 2012 | 1.693M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.1008M
Minimum
Jun 2024
9.154M
Maximum
Sep 2022
1.148M
Average
0.2762M
Median
Revenue (Quarterly) Benchmarks
| Novavax Inc | 84.51M |
| Baxter International Inc | 2.699B |
| AIM ImmunoTech Inc | 0.035M |
| Protalix BioTherapeutics Inc | 17.96M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -25.17M |
| Total Expenses (Quarterly) | 27.35M |
| EPS Diluted (Quarterly) | -0.89 |
| Enterprise Value | 21.16M |
| Earnings Yield | -110.1% |
| Normalized Earnings Yield | -116.41 |